Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) — CaboPen

Penile Squamous Cell Carcinoma Clinical Trial

Official title:
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)

Status Recruiting

Clinical Trial Summary

Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)

Clinical Trial Description

an open-label, single-center, phase 2, single-arm trial ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03943602
Study type	Interventional
Source	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact	Daniele Raggi, MD
Phone	+390223902402
Email	daniele.raggi@istitutotumori.mi.it
Status	Recruiting
Phase	Phase 2
Start date	August 1, 2019
Completion date	September 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02837042` - Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma	Phase 2
Completed	`NCT01807546` - Oral Rigosertib for Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT03774901` - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma	Phase 2
Not yet recruiting	`NCT06353906` - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer	Phase 2
Active, not recruiting	`NCT02496208` - Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	Phase 1
Active, not recruiting	`NCT02834013` - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Phase 2
Completed	`NCT06068998` - Molecular Characterization of Penile Cancers in Developing Countries